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cense.Abstract Introduction: Avascular necrosis (AVN) is a major cause of morbidity in SLE. Several
factors have been associated with the development of osteonecrosis in SLE but corticosteroid ther-
apy has been the most consistent. Many factors such as thromboembolism, fat embolism, throm-
bophilia, hypoﬁbrinolysis, intramedullary haemorrhage, vasculitis and increased bone marrow
pressure are related to corticosteroid-induced osteonecrosis.
Aim of the work: To determine the prevalence of avascular necrosis (AVN) of bone in patients with
systemic lupus erythematosus (SLE) and to study the predictive factors for AVN in patients with
SLE and its association with other SLE disease manifestations.
Patients and methods: One hundred consecutive SLE patients, diagnosed according to the updated
American College of Rheumatology criteria (ACR), were studied. A full medical history and rheu-
matologic examination were administered to all patients. Laboratory and serologic tests were also
carried out. Systemic disease activity was scored using the systemic lupus erythematosus disease
activity index (SLEDAI). Cases of symptomatic AVN were identiﬁed by plain X-ray and magnetic
resonance imaging (MRI). Comparisons between groups of patients with and without AVN, and
associations between groups were analyzed by the t-test, Pearson correlation as well as multiple
regression models to study the predictive factors for AVN in patients with SLE.6753062.
.com (R.M. Ghaleb), gihan_
salammohamed@yahoo.com
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28 R.M. Ghaleb et al.Results: AVN was detected in 15% (n= 15) of SLE patients. Osteonecrosis of one hip joint was
highly predictor for the other (p= 0.000). Cumulative corticosteroid dose, Gait disturbance, myal-
gia and hypertension are the clinical predictors of AVN (p= 0.000, 0,000, 0.001, 0.000), respec-
tively, in the regression analysis model. Haemoglobin and proteinuria were the laboratory
predictive (p= 0.000, 0.000), respectively.
Conclusions: Lupus patients are at high risk for avascular necrosis (AVN), this risk extended to
those on high dose corticosteroid of which patient’s screening should be considered and closely
monitored by sensitive techniques such as MRI.
 2010 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Avascular necrosis (AVN) is a major cause of morbidity in
SLE. Since its ﬁrst description by Dubois and Cozen in 1960
[1], AVN has been increasingly reported in SLE patients.
The prevalence rate of AVN in SLE varies widely and ranges
from 2.8% to 40% [2].
Several factors have been associated with the development
of osteonecrosis in SLE but corticosteroid therapy has been
the most consistent association [3]. Studies investigating the
association of AVN and steroid treatment yielded conﬂicting
results concerning the cumulative steroid dosage, maximum
steroid dose, route of steroid administration and the duration
of steroid treatment. AVN may develop in patients who re-
ceived high-dose, short-term steroids, long-term steroids or
even after intra-articular injection [4].
The incidence of osteonecrosis in patients administered ste-
roids for SLE is 22–44% [5,6]. It has been reported that many
factors such as thromboembolism, fat embolism, thrombo-
philia, hypoﬁbrinolysis, intramedullary haemorrhage, vasculi-
tis and increased bone marrow pressure are related to
corticosteroid-induced osteonecrosis [7–9].
On the other side, AVN has also long been recognized in
SLE patients who had not been put on steroid [1,10]. Zizic
[11] commented on the rarity of AVN in other steroid depen-
dent populations, such as asthma, dermatological diseases and
inﬂammatory bowel disorders, when compared to SLE. This
suggests that additional factors speciﬁc to SLE itself may be
responsible for AVN [4].
The diagnosis of AVN can be made using different imaging
modalities. MRI has demonstrated excellent capabilities in the
diagnosis of AVN [12,13]. MRI has also demonstrated supe-
rior sensitivity in the detection of AVN compared with conven-
tional radiography and computed tomography. Fatty bone
marrow can be differentiated from hematopoietic bone mar-
row on T1-weighted MR images [14].
The aim of this study was to assess the prevalence of AVN
of bone in patients with SLE and to study the predictive fac-
tors for AVN in patients with SLE and its association with
other SLE disease manifestations.
2. Patients and methods
2.1. Patients
One hundred consecutive SLE patients diagnosed according to
the 1997 updated revised version of the American College of
Rheumatology (ACR) criteria for the diagnosis of SLE [15] were
included in the study.Thosewere either outpatients or inpatientsof Rheumatology and Rehabilitation Department of El-Minia
University Hospital, Egypt. Patients were studied fromNovem-
ber 2008 through January 2010. A written consent from all SLE
patients was present before entering the study. All patients were
subjected to fullmedical history taking and clinical examination.
The demographic characteristics, clinical features, autoanti-
body proﬁle and information regarding corticosteroid adminis-
tration (route, total cumulative dose, mean daily dose) of the
patients were recorded.When a different preparation of cortico-
steroid was used, an equivalent dose of prednisolone was calcu-
lated. Other causes that may cause AVN include taking heparin,
pregnancy or alcohol consumption had been excluded.
2.2. SLE activity
Current SLE disease activity was measured using the SLE Dis-
ease Activity Index (SLEDAI) [16]. The SLEDAI is scored on
24 items observed during the preceding 10 days.
2.3. Disability
Assessment of disability was done using The Arabic Version of
the HAQ-Disability Index [17].
2.4. Investigations
Simple urinalysis, 24-h urinary albumin, complete blood pic-
ture (CBC), ﬁrst hour erythrocyte sedimentation rate ESR
(Westergren), serum AST and ALT, serum creatinine and
blood urea, ANA by immuno–ﬂuorescence technique, anti-ds
DNA by ELISA were done for all patients. Abdominal ultra-
sonography, slit lamp and fundus examination, skeletal and
chest X-ray, CT and EEG were done when indicated.
2.5. Imaging
Cases of symptomatic AVN were identiﬁed by plain X-ray and
by magnetic resonance imaging (MRI).
2.6. Conventional radiography
Conventional radiography of the pelvis and hip joint in AP
view and any additional views were done according to each
case requirement.
2.7. MRI examination
Two systems were used during this study, GE 1 tesla and Phi-
lips 1.5 tesla. Body coil was applied for all cases. Patients were
Table 2 Patients laboratory parameters Mean ± SD
(N= 100).
Range Minimum Maximum Mean SD
HG (gm %) 6 7.4 13.4 10.7 1.5
WBCs (mm3) 5997.300 3002.700 6000 5449.3 1651.1
Platelets (mm3) 239000 205.000 444.000 284.350 645.7
ESR 91 34 125 71.4 29.7
AST 39 4 43 16.4 9.3
ALT 60 4 64 17.95 13.4
FBS 292 78 370 108.7 61.4
Serum urea 68 17 85 36.95 14.5
Serum creatinine 1.2 0.6 1.8 0.9 0.3
Proteinuria
(gm/24 h)
6.5 0 6.5 1.6 1.9
Hb = haemoglobin, WBCs = white blood cells, ESR= erythro-
cyte sedimentation rate, AST = aspartate aminotransferase,
ALT= alanine aminotransferase, FBS = fasting blood sugar.
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400–600 ms, TE = 9–18 ms), T2 (TR= 3000–4000 ms, TE
= 100 ms), Gradient echo with 15 ﬂip angle (TR = 440 ms,
TE = 12 ms), STIR (short time inversion recovery) with inver-
sion time T1 two to three times the echo time, Post contrast T1
studies. We used I.V. injection of 0.1 mmol/kg of Gd-DTPA
(gadolinium diethylene Triamine Penta acetic acid) (Magne-
vist, Schering, Germany).
Different imaging planes were employed including axial,
coronal and sagittal planes. Both hips were imaged for com-
parison. Field of view used was 30 · 24 cm which includes
the whole hip region, slice thickness used was 7 mm, the in-
ter-slice gap employed was about 3 mm, and the matrix used
was 256 · 256. There was not a ﬁxed protocol for examination
and this is to evaluate the sensitivity of the different pulse se-
quences to detect the marrow and articular cartilage changes.
2.8. Statistical analysis
Data were analyzed by The Statistical Package for the Social
Sciences (SPSS, version 11.0 for windows) [18]. Student’s t-test
was used to compare the difference between two group
means in interval and ordinal variables. Associations between
interval, ordinal and dichotomous variables were tested by
Pearson’s Product Moment Correlation Coefﬁcients (r).
Two-tailed tests were used throughout, with statistical signiﬁ-
cance set at the conventional 95% level. Risk factors for
AVN were studied by multiple logistic regressions using
AVN as the outcome variable and other factors such as age,
age at onset, oral cumulative corticosteroid use, pulse methyl-
prednisolone, gait disturbance, and disability of the disease
itself as the predictor variables.
3. Results
3.1. Demographic data and clinical features
Among the 100 studied SLE patients, there were 91 females
(91.0%) and 9 males (9.0%), with a female to male ratio of
9:1. The mean age of patients was 25.5 ± 6.6 years with age
at onset of the disease 19.3 ± 6.5 years and disease duration
of 6.2 ± 2.8 years. Patient’s clinical characteristics are shown
in Table 1.
Antinuclear antibodies (ANA) was positive in 95%, with
double strand-DNA (ds-DNA) titer >117 positively in 80%.
Patient’s laboratory parameters are shown in Table 2.
Frequencies of clinical manifestation distribution in our pa-
tients are represented in Fig. 1.Table 1 Patients clinical characteristics Mean ± SD
(N= 100).
Range Minimum Maximum Mean SD
Age (years) 25 13 38 25.5 6.6
Age at onset (years) 22.5 8 30 19.3 6.5
Disease duration (years) 10.8 1.3 12 6.2 2.8
Articular index 58 2 60 21.2 17.4
Number of swollen joints 16 0 16 4 4.4
SLEDAI 23 7 30 19.6 7.3
HAQ 2.4 0 2.4 1.1 0.8Neither patient had cardiovascular nor gastrointestinal
manifestations. Abdominal sonar was normal in 70% of pa-
tients, while renal affection was found in 20%, renal affection
plus ascities in 5%, while renal affection plus hepatospleno-
megaly in 5%. In patients with renal affection, 30% of them
had heamaturia and 55% had pyuria. Qualitative albuminuria
of three plus or more was found in 30% of patients.
NSAIDs and steroids were in use by all patients in a vary-
ing groups and dosage. Steroids of low dose (15 mg prednis-
lone or less per day) were in use by 55% of patients, while
high dose (1–2 mg/kg/day) were in use by 45%, of whom,
20% pulsed steroid in a mega dose were in use. Table 3 repre-
senting drug intake, other than NSAIDs and corticosteroids in
SLE patients.
3.2. Imaging ﬁndings in SLE patients
On plain radiography, joint space narrowing was present in
15%, sclerosis in 10% with no cases of subcortical fracture.
On MRI technique, bone marrow oedema and subchondral
collapse were ﬁnd in 10% for each, while joint effusion was
present in 30% (Table 4). Grade II and grade III AVN is illus-
trated in Fig. 2 while grade IV is illustrated in Fig. 3.
3.3. AVN in SLE
The prevalence of osteonecrosis of bone (hip-joint) was 15% in
our SLE patient’s population. Ten percent of patients (10%)
had bilateral avascular necrosis (AVN), and the other 5%
had unilateral AVN as examined by MRI. Osteonecrosis of
one hip joint was highly predictor for the other (p= 0.000).
Osteonecrosis of the hip was positively correlated with age
(p< 0.04), age at onset of the disease (p< 0.05), HAQ
(p< 0.02). High signiﬁcant correlation was found with distur-
bance of gait (in the form of antalgic gait) (p< 0.000), pres-
ence of alopecia (p< 0.006), cushinoid face (p< 0.005),
corticosteroid dose (p< 0.000) as well as cumulative oral ste-
roid dose (p< 0.000), but inversely correlated to pulsed meth-
ylpredinsolone use (p< 0.03). Osteonecrosis was also
correlated to cyclophosphamide use (p< 0.02). Haemoglobin,
protinuria/24 h and ALT were highly signiﬁcantly correlated
with osteonecrosis hip (p< 0.000, p< 0.000, p< 0.001,
80%
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Figure 1 Distribution of clinical manifestations in SLE patients.
Table 3 Drug intake in SLE patients (N= 100).
Antimalarials 90%
Cyclophosphamide 40%
Azathioprine 70%
Antihypertensive 15%
Table 4 Imaging ﬁndings in SLE patients.
X-ray ﬁndings Frequency (%) MRI ﬁndings Frequency (%)
Sclerosis 10 Bone marrow
oedema
10
Joint space
narrowing
15 Joint eﬀusion 30
Subcortical
fracture
0 Subchondral
ollapse
10
30 R.M. Ghaleb et al.respectively). Fever, myalgia and abdominal sonographic ﬁnd-
ings were inversely correlated with osteonecrosis hip
(p< 0.002, p< 0.001, p< 0.04, respectively). Both erythro-Figure 2 Bilateral AVN, grade II atcyte sedimentation rate (ESR) and platelets number were in-
versely correlated with osteonecrosis hip (p< 0.02,
p< 0.004, respectively) as well as patients who had hyperten-
sion (p< 0.000) Table 5.
SLE patients who had AVN were signiﬁcantly older, had a
later disease onset, a higher articular index, and more disability
as measured by HAQ (p< 0.01), than SLE patients without
AVN, but the difference was not statistically different between
the two groups regarding disease duration, swollen joints,
SLEDAI or number of SLE criteria fulﬁlled (Table 6). Com-
parisons of laboratory parameters between both groups are
illustrated in (Table 7).
3.4. Risk factors for AVN
By logistic regression analysis, bilateral osteonecrosis of the
hip on the MRI was a high signiﬁcant predictor (p< 0.000)
of the other hip-joint osteonecrosis. Joint effusion as detected
by MRI image was also a signiﬁcant predictor of osteonecrosis
(p< 0.001), while sclerosis on X-ray image was a high signif-
icant predictor (p< 0.000) of hip-joint osteonecrosis.right side & grade III at left side.
Figure 3 Bilateral AVN grade IV.
Table 5 Correlation of the presence of AVN in lupus patients
(N= 100).
AVN
r p
Age 0.20 0.04*
Age at onset 0.19 0.05*
Disease duration 0.02 0.82
Fever 0.31 0.002**
Arthritis 0.14 0.16
Articular index 0.35 0.000**
Renal aﬀection 0.27 0.006**
Hypertension 0.27 0.001**
Cushinoid face 0.28 0.005**
Disturbance of gait 0.79 0.000**
HB 0.40 0.000**
ESR 0.23 0.02*
Proteinuria 0.36 0.000**
HAQ 0.23 0.02*
SLEADI 0.17 0.09
Cumulative dose of corticosteroid 0.61 0.000**
Pulse methylpredisolone 0.21 0.04*
* p< 0.05.
** p< 0.005.
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blood pressure, haemoglobin level and proteinuria were the
other signiﬁcant predictors of osteonecrosis hip-joint in our
SLE patients group (p< 0.000, p< 0.001, p< 0.000,
p< 0.000, p< 0.000, p< 0.000, respectively).Table 6 Comparison between SLE patients with and without AVN
AVN +ve (n= 15)
Mean ± SD
Age of the patient (years) 28.7 ± 3.4
Age at onset (years) 22.3 ± 4.3
Disease duration (years) 6.3 ± 3.0
Articular index 38.7 ± 7.4
Number of swollen joints 2.7 ± 2.6
HAQ disability 1.5 ± 0.4
SLEDAI 16.7 ± 7.7
ACR criteria 7.4 ± 0.94. Discussion
The goal of this study was to report how is osteonecrosis of
bone, especially hip-joint, prevalent in patients with SLE,
and to study the most predictive factors in the asymptomatic
hip of patients, as many authors have indicated that the extent
of the necrotic lesion is signiﬁcantly affects the outcome of the
disease.
It is well known that patients who have bilateral osteone-
crosis of the femoral head may have pain in one or both hips.
A clinical dilemma that commonly arises in the assessment of
an asymptomatic, radiographically normal hip, but with an
abnormal MRI scan at the time that the contralateral hip is
evaluated for pain is to determine the outcome of the asymp-
tomatic diseased femoral head. It is not known how many
asymptomatic hips with normal ﬁndings on initial radio-
graphs, but with an abnormal MRI scan, will eventually man-
ifest symptoms and radiological changes. The common clinical
challenge is the treatment (or not) of such asymptomatic hip to
safe the patient from the subsequent outcome.
AVN was detected in 15 of our SLE patients (15%), in
accordance with a prevalence of 14.5% in a study by Petri of
407 unselected SLE patients [19], and slightly lower than a
prevalence of 22% in a study of 46 SLE patients by Fialho
et al. [20]. Both studies determined the prevalence of avascular
necrosis using MRI.
A lower prevalence of AVN in SLE patients compared to
our study was found in a study by Migliaresi et al. [21] in
which AVN occurred in seven of 69 unselected SLE patients
(10.14%). Another study by Mok et al. [22] giving a pointregarding demographic and SLE disease-related variables.
AVN ve (n= 85)
Mean ± SD
Diﬀerence
t p
24.9 ± 6.8 3.2 0.003*
18.8 ± 6.6 2.7 0.01*
6.1 ± 2.8 0.23 0.82
21.7 ± 17.6 3.7 0.001*
4.2 ± 4.3 1.9 0.06
1.0 ± 0.8 3.6 0.001*
20.1 ± 7.1 1.6 0.12
6.4 ± 1.4 1.8 0.09
Table 7 Comparison between SLE patients with and without AVN and SLE regarding laboratory parameters.
AVN +ve (n= 15)
Mean ± SD
AVN ve (n= 85)
Mean ± SD
Diﬀerence
t p
Hb 12.1 ± 1.2 10.4 ± 1.4 4.4 0.000*
WBCs 4033.3 ± 846.6 4941.2 ± 1628.6 3.2 0.003*
Platelets 241000.0 ± 17464.2 292000.0 ± 66841.1 6.0 0.000*
ESR 55.3 ± 15.6 74.2 ± 30.7 3.6 0.001*
Urea 30.3 ± 7.0 38.1 ± 15.2 3.2 0.003*
Creatinine 0.8 ± 0.1 1.0 ± 0.3 3.2 0.002*
AST 16.0 ± 7.4 16.4 ± 9.6 0.16 0.87
ALT 28.0 ± 26.5 16.2 ± 8.6 3.3 0.001*
FBS 87.3 ± 8.2 112.5 ± 65.8 3.4 0.001*
Proteinuria (gm/24 h) 3.2 ± 2.5 1.3 ± 1.6 3.8 0.000*
32 R.M. Ghaleb et al.prevalence of 4%, of which eleven patients had AVN among
265 SLE patients.
The main explanation for this discrepancy could be due to
the variability of the method used to determine AVN either by
using conventional radiography, computed tomography, MRI
technique or radioisotope scan, difference in corticosteroid
dose, or due to the potential ethnic differences in the frequency
or expression of AVN in lupus patients.
The use of corticosteroids in the treatment of SLE has
blurred the distinction between the role of the disease itself
and that of the treatment in the pathogenesis of AVN. Cortic-
osteriod use is the chief risk factor for AVN in SLE in many
studies. However, studies investigating the association of
AVN and steroid treatment in SLE yielded conﬂicting results.
Smith et al. [23] and Dimant et al. [24] did not ﬁnd any asso-
ciation between the total cumulative doses of steroid, the dura-
tion of therapy or the peak steroid dose with AVN. Bergstein
et al. [25] described a relationship between AVN and the total
cumulative steroid dose, but not with the duration of steroid
treatment. Moreover, whether steroid induced AVN occurs
slowly over a long period of time, or abruptly after a brief per-
iod of high-dose treatment, remains controversial. Massardo
et al. [26] considered IV pulse methylprednisolone as a risk fac-
tor for AVN. However, this was not supported by Migliaresi
et al. [21], who failed to ﬁnd an increased risk of AVN in pa-
tients receiving IV pulse steroid therapy.
Our study, ﬁndings indicate that both of steroid dose and
cumulative dose of corticosteroid was strongly associated
and predictive of AVN. In other study, AVN has been re-
ported in untreated SLE patients; 11 patients with AVN out
of 400 adult SLE patients. One had never received corticoste-
roids, ﬁve had received no corticosteroids for many months to
years before the onset of clinical manifestations and the
remaining ﬁve had received doses equivalent to 10–30 mg of
prednisone daily [1].
In our study, there was an association between intravenous
pulse methylprednisolone and AVN and this is in accordance
with a study by Massardo et al. [26]. In that study, a retrospec-
tive analysis of 190 patients with SLE was done and they found
that 19% of 36 patients treated with pulse methylprednisolone
had osteonecrosis compared with 6% of 154 patients without
that treatment (p< 0.04). Risk factors associated with osteo-
necrosis were pulse methylprednisolone treatment, cushingoid
appearance and steroid doses. In a stepwise regression model,
when cushingoid appearance was excluded, pulse methylpred-
nisolone became the only signiﬁcant factor (p= 0.045).On the contrary, Mok et al. [4] found no association be-
tween pulse steroid and AVN. This discrepancy may be due
to that the number of patients who received pulse methylpred-
nisolone is too small for comparison with those who received
oral corticosteroid leading to type II statistical error.
Regarding disease activity as a risk factor in developing oste-
onecrosis, in our study no association was found between lupus
activity measured by SLEDAI and AVN. This is in accordance
with Mok et al. study [4] in which SLEDAI score was higher in
patients with AVN than in those patients without AVN, but this
did not reach statistical signiﬁcance. On the contrary to our
study, Fialho et al. [20], studied 46 consecutive SLE patients
[20], only SLEADI remained as an independent risk factor for
AVN so it is considered as the main predictor factor for the
development of osteonecrosis in their study.
This study documents and supports the role of cumulative
dose corticosteroid to predict AVN in lupus patients and high-
lights the value of screening lupus patients by sensitive MRI
technique for the presence of AVN. Monitoring and recording
for early change or disturbance of gait in the presence of myal-
gic symptoms and elevated systolic blood pressure, which are
the predictors of AVN occurrence in this study.
In conclusion, we believe that the etiology of AVN in SLE is
multifactorial. Corticosteriod remains the chief predisposing
factor for AVN in SLE patients and its use should be judicious.
More sensitive techniques, such as MRI should be considered
for the early diagnosis ofAVN in this groupof high risk patients.
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